Ⅲ章 資料


文献

 胃癌治療を理解・実践する上で有用と思われる文献を英文論文を中心に集め,各分野ごとに出版年順にリストした(1)2)…)。ガイドライン本文の記述と直接関係するものは,本文中に文献番号([1][2]…)を記した。

外科治療に関する論文

リンパ節郭清に関する文献

1) Bonenkamp JJ, Hermans J, Sasako M, et al:Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908-14.
2) Cuschieri A, Weeden S, Fielding J, et al:Patient survival after D1 and D2 resections for gastric cancer:long-term results of the MRC randomized surgical trial. Br J Cancer 1999;79:1522-30.
3) Wu CW, Hsiung CA, Lo SS, et al:Randomized clinical trial of morbidity after D1 and D3 surgery for gastric cancer. Br J Surg 2004;91:283-87.
4) Degiuli M, Sasako M, Calgaro M, et al:Morbidity and mortality after D1 and D2 gastrectomy for cancer:interim analysis of the Italian gastric cancer study group(IGCSG)randomised surgical trial. EJSO 2004;30:303-8.
5) Sano T, Sasako M, Yamamoto S, et al:Gastric cancer Surgery:Morbidity and mortality results from a prospective randomized controlled trial compariwng D2 and extended para-aortic lymphadenectomy―Japan clinical oncology group study 9501. J Clin Oncol 2004;22:2767-73.
6) Kodera Y, Sasako M, Yamamoto S, et al:Identification of risk factors for the development of complications following extended and surperextended lymphadenectomies for gastric cancer. Br J Surg 2005;92:1103-09.
7) Sasako M, Sano T, Yamamoto S, et al:Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia:a randomised controlled trial. Lancet Oncol 2006;7:644-51.
8) Marrelli D, Pedrazzani C, Neri A, et al:Complications after extended(D2)and superextended(D3)lymphadenectomy for gastric cancer:Analysis of potential risk factors. Ann Surg Oncol 2007;14:25-33.
9) Yonemura Y, Wu CC, Fukushima N, et al:Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol 2008;13:132-37.
10) Sasako M, Sano T, Yamamoto S, et al:D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Eng J Med 2008;359:453-62.
11) Tokunaga M, Ohyama S, Hiki N, et al:Therapeutic value of lymph node dissection in advanced gastric cancer with macroscopic duodenum invasion:is the posterior pancreatic head lymph node dissection beneficial? Ann Surg Oncol 2009;16:1241-46.
12) Songun I, Putter H, Kranenbarg EM, et al:Surgical treatment of gastric cancer:15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-49.
13) Tanizawa Y, Terashima M:Lymph node dissection in the resection of gastric cancer:review of existing evidence. Gastric Cancer 2010;13:137-48.
14) Lips DJ, Schutte HW, van der Linden RL, et al:Sentinel lymph node biopsy to direct treatment in gastric cancer. A systematic review of the literature. Eur J Surg Oncol 2011;37:655-61.
15) Yamashita H, Katai H, Morita S, et al:Optimal extent of lymph node dissection for Siewert type Ⅱ esophagogastric junction carcinoma. Ann Surg 2011;254:274-80.
16) Seevaratnam R, Bocicariu A, Cardoso R, et al:How many lymph nodes should be assessed in patients with gastric cancer? A systematic review. Gastric Cancer 2012;15:S70-88.
17) Eom BW, Joo J, Kim YW, et al:Is there any role of additional retropancreatic lymph node dissection on D2 gastrectomy for advanced gastric cancer? Ann Surg Oncol 2013;20:2669-75.
18) Lee HH, Yoo HM, Song KY, et al:Risk of limited lymph node dissection in patients with clinically early gastric cancer:indications of extended lymph node dissection for early gastric cancer. Ann Surg Oncol 2013;20:3534-40.
19) Asoglu O, Matlim T, Kurt A, et al:Guidelines for extended lymphadenectomy in gastric cancer:a prospective comparative study. Ann Surg Oncol 2013;20:218-25.
20) Kitagawa Y, Takeuchi H, Takagi Y, et al:Sentinel node mapping for gastric cancer:a prospective multicenter trial in Japan. J Clin Oncol 2013;31:3704-10.

脾摘および膵切除に関する文献

21) Maehara Y, Moriguchi S, Yoshida M, et al:Splenectomy does not correlate with length of survival in patients undergoing curative total gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer 1991;67:3006-9.
22) Maruyama K, Sasako M, Kinoshita T, et al:Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg 1995;19:532-6.
23) Otsuji E, Yamaguchi T, Sawai K, et al:Total gastrectomy with simultaneous pancreaticosplenectomy or splenectomy in patients with advanced gastric carcinoma. Br J Cancer 1999;79:1789-93.
24) Sano T, Yamamoto S, Sasako M:Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma:Japan clinical oncology group study JCOG 0110-MF. Jpn J Clin Oncol 2002;32:363-4.
25) Csendes A, Burdiles P, Rojas J, et al:A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 2002;131:401-7.
26) Yu W, Choi GS, Chung HY:Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006;93:559-63.
27) Cheong O, Kim BS, Yook JH, et al:Modified radical lymphadenectomy without splenectomy in patients with proximal gastric cancer:comparison with standard D2 lymphadenectomy for distal gastric cancer. J Surg Oncol 2008;98:500-4.
28) Zhu GL, Sun Z, Wang ZN, et al:Splenic hilar lymph node metastasis independently predicts poor survival for patients with gastric cancers in the upper and/or the middle third of the stomach. J Surg Oncol 2012;105:786-92.
29) Brar SS, Seevaratnam R, Cardoso R, et al:A systematic review of spleen and pancreas preservation in extended lymphadenectomy for gastric cancer. Gastric Cancer 2012;15 Suppl 1:S89-99.

縮小手術の適応と効用に関する文献

30) Katai H, Sano T, Fukagawa T, et al:Prospective study of proximal gastrectomy for early gastric cancer in the upper third of the stomach. Br J Surg 2003;90:850-3.
31) Shibata C, Shiiba KI, Funayama Y, et al:Outcomes after pylorus-preserving gastrectomy for early gastric cancer:a prospective multicenter trial. World J Surg 2004;28:857-61.
32) Kitagawa Y, Kitano S, Kubota T, et al:Minimally invasive surgery for gastric cancer-toward a confluence of two major streams:a review. Gastric Cancer 2005;8:103-10.
33) Ohdaira H, Nimura H, Mitsumori N, et al:Validity of modified gastrectomy combined with sentinel node navigation surgery for early gastric cancer. Gastric Cancer 2007;10:117-22.
34) Park do J, Lee HJ, Jung HC, et al:Clinical outcome of pylorus-preserving gastrectomy in gastric cancer in comparison with conventional distal gastrectomy with Billroth I anastomosis. World J Surg 2008;32:1029-36.
35) Morita S, Katai H, Saka M, et al:Outcome of pylorus-preserving gastrectomy for early gastric cancer. Br J Cancer 2008;95:1131-5.
36) Ishikawa S, Shimada S, Miyanari N, et al:Pattern of lymph node involvement in proximal gastric cancer. World J Surg 2009;33:1687-92.
37) Hiki N, Sano T, Fukunaga T, Ohyama S, et al:Survival benefit of pylorus-preserving gastrectomy in early gastric cancer. J Am Coll Surg 2009;209:297-301.
38) Mine S, Sano T, Tsutsumi K, et al:Large-scale investigation into dumping syndrome after gastrectomy for gastric cancer. J Am Coll Surg 2010;211:628-36.
39) Morita S, Sasako M, Saka M, et al:Correlation between the length of the pyloric cuff and postoperative evaluation after pylorus-preserving gastrectomy. Gastric Cancer 2010;13:109-16.
40) Jiang X, Hiki N, Nunobe S, et al:Postoperative outcomes and complications after laparoscopy-assisted pylorus-preserving gastrectomy for early gastric cancer. Ann Surg 2011;253:928-33.
41) Koeda K, Nishizuka S, Wakabayashi G:Minimally invasive surgery for gastric cancer:the future standard of care. World J Surg 2011;35:1469-77.
42) Hayami M, Seshimo A, Miyake K, et al:Effects of emptying function of remaining stomach on QOL in postgastrectomy patients. World J Surg 2012;36:373-8.
43) Tomikawa M, Korenaga D, Akahoshi T, et al:Quality of life after laparoscopy-assisted pylorus-preserving gastrectomy:an evaluation using a questionnaire mailed to the patients. Surg Today 2012;42:625-32.
44) Karanicolas PJ, Graham D, Gonen M, et al:Quality of life after gastrectomy for adenocarcinoma:a prospective cohort study. Ann Surg 2013;257:1039-46.
45) Kinoshita T, Gotohda N, Kato Y, et al:Laparoscopic proximal gastrectomy with jejunal interposition for gastric cancer in the proximal third of the stomach:a retrospective comparison with open surgery. Surg Endosc 2013;27:146-53.
46) Nozaki I, Hato S, Kobatake T, et al:Long-term outcome after proximal gastrectomy with jejunal interposition for gastric cancer compared with total gastrectomy. World J Surg 2013;37:558-64.

胃癌に対する拡大手術・肝切除に関する文献

47) Furukawa H, Hiratsuka M, Iwanaga T, et al:Extended surgery―left upper abdominal exenteration plus Appleby’s method―for type 4 gastric carcinoma. Ann Surg Oncol 1997;4:209-14.
48) Nomura E, Niki M, Fujii K, et al:Efficacy of intraperitoneal and intravenous chemotherapy and left upper abdominal evisceration for advanced gastric cancer. Gastric Cancer 2001;4:75-82.
49) Ambiru S, Miyazaki M, Ito H, et al:Benefits and limits of hepatic resection for gastric metastases. Am J Surg 2001;181:279-83.
50) Okano K, Maeba T, Ishimura K, et al:Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 2002;235:86-91.
51) Shirabe K, Shimada M, Matsumata T, et al:Analysis of the prognostic factors for liver metastasis of gastric cancer after hepatic resection:a multi-institutional study of the indications for resection. Hepatogastroenterol 2003;50:1560-3.
52) Saka M, Mudan SS, Katai H, et al:Pancreaticoduodenectomy for advanced gastric cancer. Gastric Cancer 2005;8:1-5.
53) Sakamoto Y, Sano T, Shimada K, et al:Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer. J Surg Oncol 2007;95:534-9.
54) Nunobe S, Hiki N, Ohyama S, et al:Survival benefits of pancreatoduodenectomy for gastric cancer:relationship to the number of lymph node metastases. Langenbecks Arch Surg 2008;393:157-62.
55) Tiberio GA, Coniglio A, Marchet A, et al:Metachronous hepatic metastases from gastric carcinoma:A multicentric survey. EJSO 2009;35:486-91.
56) Dittmar Y, Altendorf-Hofmann A, Rauchfuss F, et al:Resection of liver metastases is beneficial in patients with gastric cancer:report on 15 cases and review of literature. Gastric Cancer 2012;15:131-6.
57) Romano F, Garancini M, Uggeri F, et al:Surgical treatment of liver metastases of gastric cancer:state of the art. World J Surg Oncol 2012;10:157.
58) Schildberg CW, Croner R, Merkel S, et al:Outcome of operative therapy of hepatic metastatic stomach carcinoma:a retrospective analysis. World J Surg 2012;36:872-8.
59) Takemura N, Saiura A, Koga R, et al:Long-term outcomes after surgical resection for gastric cancer liver metastasis:an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg 2012;397:951-7.
60) Chen L, Song MQ, Lin HZ, et al:Chemotherapy and resection for gastric cancer with synchronous liver metastases. World J Gastroenterol 2013;19:2097-103.

胃癌に対する減量手術または姑息手術に関する文献

61) Kaminishi M, Yamaguchi H, Shimizu N, et al:Stomach-partitioning gastrojejunostomy for unresectable gastric carcinoma. Arch Surg 1997;132:184-7.
62) Hartgrink HH, Putter H, Klein Kranenbarg E, et al:Value of palliative resection in gastric cancer. Br J Surg 2002;89:1438-43.
63) Sarela AI, Yelluri S:Gastric adenocarcinoma with distant metastasis. Arch Surg 2007;142:143-9.
64) Fujitani K, Yang HK, Kurokawa Y, et al:Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor:Japan Clinical Oncology Group study JCOG 0705 and Korea Gastric Cancer Association study KGCA01. Jpn J Clin Oncol 2008;38:504-6.
65) Saito H, Yamada Y, Tsujitani S, et al:Clinicopathologic characteristics of gastric cancer patients who underwent noncurative gastrectomy with long-term survival. Langenbecks Arch Surg 2009;394:99-103.
66) Huang KH, Wu CW, Fang WL, et al:Palliative resection in noncurative gastric cancer patients. World J Surg 2010;34:1015-21.
67) Chang YR, Han DS, Kong SH, et al:The value of palliative gastrectomy in gastric cancer with distant metastasis. Ann Surg Oncol 2012;19:1231-9.
68) Mahar AL, Coburn NG, Singh S, et al:A systematic review of surgery for non-curative gastric cancer. Gastric Cancer 2012;15 Suppl 1:S125-37.
69) Keränen I, Kylänpää L, Udd M, et al:Gastric outlet obstruction in gastric cancer:a comparison of three palliative methods. J Surg Oncol 2013;108:537-41.
70) Mariette C, Bruyere E, Messager M, et al:Palliative resection for advanced gastric and junctional adenocarcinoma:which patients will benefit from surgery? Ann Surg Oncol 2013;20:1240-9.
71) Sun J, Song Y, Wang Z, et al:Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer:a systematic review and meta-analysis. BMC Cancer 2013;13:577.
72) Takeno A, Takiguchi S, Fujita J, et al:Clinical outcome and indications for palliative gastrojejunostomy in unresectable advanced gastric cancer:multi-institutional retrospective analysis. Ann Surg Oncol 2013;20:3527-33.

腹腔鏡下手術に関する文献

73) Kitano S, Iso Y, Moriyama M, et al:Laparoscopy-assisted Billroth I gastrectomy. Surg Laparosc Endosc 1994;4:146-8.
74) Huscher CG, Mingoli A, Sgarzini G, et al:Laparoscopic versus open subtotal gastrectomy for distal gastric cancer. Ann Surg 2005;241:232-7.
75) Kitano S, Shiraishi N, Uyama I, et al:A multicenter study on oncologic outcome of laparoscopic gastrectomy for early cancer in Japan. Ann Surg 2007;245:68-72.
76) Yasuda K, Shiraishi N, Etoh T, et al:Long-term quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer. Surg Endosc 2007;21:2150-3.
77) Cho GS, Kim W, Kim HH, et al:Multicentre study of the safety of laparoscopic subtotal gastrectomy for gastric cancer in the elderly. Br J Surg 2009;96:1437-42.
78) Song J, Lee HJ, Cho GS, et al:Recurrence following laparoscopy-assisted gastrectomy for gastric cancer:a multicenter retrospective analysis of 1,417 patients. Ann Surg Oncol 2010;17:1777-86.
79) Kim HH, Hyung WJ, Cho GS, et al:Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer:an interim report--a phase Ⅲ multicenter, prospective, randomized Trial(KLASS Trial). Ann Surg 2010;251:417-20.
80) Katai H, Sasako M, Fukuda H, et al:Safety and feasibility of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage Ⅰ gastric cancer:a multicenter phase Ⅱ trial(JCOG 0703). Gastric Cancer 2010;13:238-44.
81) Park do J, Han SU, Hyung WJ, et al:Long-term outcomes after laparoscopy-assisted gastrectomy for advanced gastric cancer:a large-scale multicenter retrospective study. Surg Endosc 2012;26:1548-53.
82) Nakamura K, Katai H, Mizusawa J, et al:A phase Ⅲ study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage ⅠA/ⅠB gastric Cancer(JCOG0912). Jpn J Clin Oncol 2013;43:324-7.
83) Suh YS, Han DS, Kong SH, et al:Laparoscopy-assisted pylorus-preserving gastrectomy is better than laparoscopy-assisted distal gastrectomy for middle-third early gastric cancer. Ann Surg 2014;259:485-93.
84) Takiguchi S, Fujiwara Y, Yamasaki M, et al:Laparoscopy-assisted distal gastrectomy versus open distal gastrectomy. A prospective randomized single-blind study. World J Surg 2013;37:2379-86.
85) Yu J, Hu J, Huang C, et al:The impact of age and comorbidity on postoperative complications in patients with advanced gastric cancer after laparoscopic D2 gastrectomy:results from the Chinese laparoscropic gastrointestinal surgery study(CLASS)group. Eur J Surg Oncol 2013;39:1144-9.

網囊切除に関する文献

86) Imamura H, Kurokawa Y, Kawada J, et al:Influence of bursectomy on operative morbidity and mortality after radical gastrectomy for gastric cancer:results of a randomized controlled trial. World J Surg 2011;35:625-30.
87) Fujita J, Kurokawa Y, Sugimoto T, et al:Survival benefit of bursectomy in patients with resectable gastric cancer:interim analysis results of a randomized controlled trial. Gastric Cancer 2012;15:42-8.
88) Eom BW, Joo J, Kim YW, et al:Role of bursectomy for advanced gastric cancer:result of a case-control study from a large volume hospital. Eur J Surg Oncol 2013;39:1407-14.

内視鏡治療に関する論文

内視鏡診断と内視鏡治療の適応

89) Yao K, Anagnostopoulos GK, Ragunath K:Magnifying endoscopy for diagnosing and delineating early gastric cancer. Endoscopy 2009;41:462-8.
90) Ezoe Y, Muto M, Horimatsu T, et al:Magnifying narrow-band imaging versus magnifying white-light imaging for the differential diagnosis of gastric small depressive lesions:a prospective study. Gastrointest Endosc 2010;71:477-84.
91) Gotoda T, Yanagisawa A, Sasako M, et al:Incidence of lymph node metastasis from early gastric cancer:estimation with a large number of cases at two large centers, Gastric Cancer 2000;3:219-25.
92) Hanaoka N, Tanabe S, Mikami T, et al:Mixed-histologic-type submucosal invasive gastric cancer as a risk factor for lymph node metastasis:feasibility of endoscopic submucosal dissection. Endoscopy 2009;41:427-32.
93) Hirasawa T, Gotoda T, Miyata S, et al:Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer. Gastric Cancer. 2009;12:148-52.
94) Kim JH, Lee YC, Kim H, et al:Addictive lymph node dissection may be necessary in minute submucosal cancer of the stomach after endoscopic resection. Ann Surg Oncol 2012;19:779-85.
95) Lee JI, Kim JH, Kim JH, et al:Indication for endoscopic treatment of ulcerative early gastric cancer according to depth of ulcer and morphological change. J Gastroenterol Hepatol 2012;27:1718-25.
96) 滝沢耕平,川田登,田中雅樹,他:組織混在パターン別粘膜内胃癌の臨床病理学的特徴 早期胃癌外科切除例からの検討および多施設調査結果.胃と腸2013;48:1567-79.

内視鏡治療の手技・技術

97) Hirao M, Masuda K, Asanuma T, et al:Endoscopic resection of early gastric cancer and other tumors with local injection of hypertonic saline-epinephrine. Gastrointest Endosc 1988;34:264-9.
98) Tada M, Murakami A, Karita M, et al:Endoscopic resection of early gastric cancer. Endoscopy 1993;25:445-50.
99) Inoue H, Takeshita K, Hori H, et al:Endoscopic mucosal resection with a cap-fitted panendoscope for esophagus, stomach, and colon mucosal lesions. Gastrointest Endosc 1993;39:58-62.
100) 小野裕之,後藤田卓志,近藤仁,他:ITナイフを用いたEMR―適応拡大の工夫―.消化器内視鏡1999;11:675.
101) Oyama T, Kikuchi Y:Aggressive endoscopic mucosal resection in the upper GI tract-hook knife EMR method. Minim Invasive Ther Allied Technol 2002;11:291-5.
102) Ono H, Hasuike N, Inui T, et al:Usefulness of a novel electrosurgical knife, the insulation-tipped diathermic knife-2, for endoscopic submucosal dissection of early gastric cancer. Gastric Cancer 2008;11:47-52.
103) Mori H, Rafiq K, Kobara H, et al:Local steroid injection into the artificial ulcer created by endoscopic submucosal dissection for gastric cancer:prevention of gastric deformity. Endoscopy 2012;44:641-8.
104) Sasaki T, Tanabe S, Azuma M, et al:Propofol sedation with bispectral index monitoring is useful for endoscopic submucosal dissection:a randomized prospective phase Ⅱ clinical trial. Endoscopy 2012;44:584-9.
105) Maeda Y, Hirasawa D, Fujita N, et al:A prospective, randomized, double-blind, controlled trial on the efficacy of carbon dioxide insufflation in gastric endoscopic submucosal dissection. Endoscopy 2013;45:335-41.

内視鏡治療の成績・その他

106) Ono H, Kondo H, Gotoda T, et al:Endoscopic mucosal resection for treatment of early gastric cancer. Gut 2001;48:225-9.
107) Coda S, Oda I, Gotoda T, et al:Risk factors for cardiac and pyloric stenosis after endoscopic submucosal dissection, and efficacy of endoscopic balloon dilation treatment. Endoscopy 2009;41:421-6.
108) 草野 央,後藤田卓志,岩崎 基,他:早期胃癌に対する内視鏡的切除後の長期予後.胃と腸2008;43:74-80.
109) Fukase K, Kato M, Kikuchi S, et al:Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer:an open-label, randomised controlled trial. Lancet 2008;372:392-7.
110) Abe N, Gotoda T, Hirasawa T, et al:Multicenter study of the long-term outcomes of endoscopic submucosal dissection for early gastric cancer in patients 80 years of age or older. Gastric Cancer 2012;15:70-5.
111) Toyokawa T, Inaba T, Omote S, et al:Risk factors for perforation and delayed bleeding associated with endoscopic submucosal dissection for early gastric neoplasms:analysis of 1123 lesions. J Gastroenterol Hepatol 2012;27:907-12.
112) Abe S, Oda I, Suzuki H, et al:Short- and long-term outcomes of endoscopic submucosal dissection for undifferentiated early gastric cancer. Endoscopy 2013;45:703-7.
113) Kato M, Nishida T, Yamamoto K, et al:Scheduled endoscopic surveillance controls secondary cancer after curative endoscopic resection for early gastric cancer:a multicentre retrospective cohort study by Osaka University ESD study group. Gut 2013;62:1425-32.
114) Kim M, Jeon SW, Cho KB, et al:Predictive risk factors of perforation in gastric endoscopic submucosal dissection for early gastric cancer:a large, multicenter study. Surg Endosc 2013;27:1372-8.
115) Yamada M, Oda I, Nonaka S, et al:Long-term outcome of endoscopic resection of superficial adenocarcinoma of the esophagogastric junction. Endoscopy 2013;45:992-6.

化学療法に関する論文

切除不能・再発胃癌の化学療法に関する論文

116) Pyrhönen S, Kuitunen T, Nyandoto P, et al:Randomized comparison of fluorouracil, epidoxorubicin and methotrexate(FEMTX)plus supportive care with best supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
117) Vanhoefer U, Rougier P, Wilke H, et al:Final results of a randomized phase Ⅲ trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus infusional fluorouracil and cisplatin in advanced gastric cancer:a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 2000;18:2648-57.
118) Ohtsu A, Shimada Y, Shirao K, et al:Randomized phase Ⅲ trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with advanced gastric cancer:JCOG study 9205. J Clin Oncol 2003;21:54-9.
119) Cutsem EV, Moiseyenko VM, Tjulandin S, et al:Phase Ⅲ study of docetaxel with cisplatin and 5-fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 study group. J Clin Oncol 2006;24:4991-7.
120) Cunningham D, Starling N, Rao S, et al:Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
121) Koizumi W, Narahara H, Hara T, et al:Randomized phase Ⅲ study of S-1 alone versus S-1+cisplatin in the treatment for advanced gastric cancer(The SPIRITS trial)SPIRITS:S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer. Lancet Oncol 2008;9:215-21.
122) Imamura H, Iishi H, Tsuburaya A, et al:Randomized phase Ⅲ study of irinotecan plus S-1(IRIS)versus S-1 alone as first-line treatment for advanced gastric cancer(GC0301/TOP-002). 2008 Gastrointestinal Cancer Symposium.
123) Boku N, Yamamoto S, Shirao K, et al:Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer:a randomized phase3 study. Lancet Oncol 2009;10:1063-9.
124) Shirao K, Boku N, Yamada Y, et al:Randomized phase Ⅲ study of 5-fluorouracil continuous infusion(5-FUci)versus methotrexate and 5-FU sequential(MF)in gastric cancer with peritoneal metastasis:JCOG 0106. Proc Am Soci Clin Oncol 2009;27:#4545.
125) Ajani JA, Rodriguez W, Bodoky G, et al:Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study:The FLAGS trial. J Clin Oncol 2010;28:1547-53.
126) Bang YJ, Van Cutsem E, Feyereislova A, et al:Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
127) Kang Y, Ohtsu A, Cutsem EV, et al:AVAGAST:A randomized, double-blind, placebo-controlled, phase Ⅲ study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer. Proc Am Soci Clin Oncol 2010;28:LBA4007.
128) Thuss-Patience PC, Kretzschmar A, Bichev D, et al:Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase Ⅲ study of the Arbeitsgemeinschaft Internistische Onkologie(AIO). Eur J Cancer 2011;47:2306-14.
129) Choi YH, Oh SC, Kim JS, et al:A phase Ⅱ study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment:a Korean Cancer Study Group Protocol ST06-02. Cancer Chemother Pharmacol 2012;70:665-72.
130) Kang JH, Lee SI, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer:A randomized phase Ⅲ trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012;30:1513-8.
131) Imano M, Yasuda A, Itoh T, et al:Phase Ⅱ study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis. J Gastrointest Surg 2012;16:2190-6.
132) Ajani JA, Buyse M, Lichinitser M, et al:Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma:Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer 2013;49:3616-24.
133) Fushida S, Kinoshita J, Kaji M, et al:Phase Ⅰ/Ⅱ study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol 2013;71:1265-72.
134) Hironaka S, Ueda S, Yasui H, et al:Randomized, open-label, phase Ⅲ study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum:WJOG 4007 trial. J Clin Oncol 2013;31:4438-44.
135) Huang D, Ba Y, Xiong J, et al:A multicentre randomised trial comparing weekly paclitaxel+S-1 with weekly paclitaxel+5-fluorouracil for patients with advanced gastric cancer. Eur J Cancer 2013;49:2995-3002.
136) Kunisaki C, Takahashi M, Ono HA, et al:Biweekly Docetaxel and S-1 combination chemotherapy as first-line treatment for elderly patients with advanced gastric cancer. Anticancer Res 2013;33:697-704.
137) Li J, Qin S, Xu J, et al:Apatinib for chemotherapy-refractory advanced metastatic gastric cancer:results from a randomized, placebo-controlled, parallel-arm, phase Ⅱ trial. J Clin Oncol 2013;31:3219-25.
138) Lordick F, Kang YK, Chung HC, et al:Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer(EXPAND):a randomised, open-label phase 3 trial. Lancet Oncol 2013;14:490-9.
139) Mochizuki Y, Ohashi N, Kojima H, et al:CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1(CCOG0702). Cancer Chemother Pharmacol 2013;72:629-35.
140) Ohtsu A, Ajani JA, Bai YX, et al:Everolimus for previously treated advanced gastric cancer:results of the randomized, double-blind, phase Ⅲ GRANITE-1 study. J Clin Oncol 2013;31:3935-43.
141) Richards D, Kocs DM, Spira AI, et al:Results of docetaxel plus oxaliplatin(DOCOX)±cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma:results of a randomised Phase 2 study. Eur J Cancer 2013;49:2823-31.
142) Sakai D, Satoh T, Kurokawa Y, et al:A phase Ⅱ trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer:Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203(HERBIS-5). Jpn J Clin Oncol 2013;43:838-40.
143) Shirao K, Boku N, Yamada Y, et al:Randomized Phase Ⅲ study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis(JCOG0106). Jpn J Clin Oncol 2013;43:972-80.
144) Waddell T, Chau I, Cunningham D, et al:Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer(REAL3):a randomised, open-label phase 3 trial. Lancet Oncol 2013;14:481-9.
145) Yamaguchi H, Kitayama J, Ishigami H, et al:A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer 2013;119:3354-8.
146) Yoshino S, Furuya T, Shimizu R, et al:Combination phase Ⅱ study of weekly paclitaxel and 5’-DFUR for unresectable or recurrent gastric cancer. Anticancer Res 2013;33:2629-33.
147) Koizumi W, Kim YH, Fujii M, et al:Addition of decetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer:a randomized study(START). J Cancer Res Clin Oncol 2014;140:319-28.

補助化学療法に関する論文

148) Furukawa H, Iwanaga T, Nakajima T, et al:Randomized study with mitomycin C+5-fluorouracil+cytosine arabinoside(MFC)+5-fluorouracil, MFC+tegafur and uracil(UFT), and MF+UFT in advanced gastric cancer:interinstitutional differences in a multicenter study in Japan. J Surg Oncol 1995;60:59-64.
149) Nakajima T, Nashimoto A, Kitamura M, et al:Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer:a randomised trial. Gastric Cancer Surgical Study Group. Lancet 1999;354:273-7.
150) Mari E, Floriani I, Tinazzi A, et al:Efficacy of adjuvant chemotherapy after curative resection for gastric cancer:a meta-analysis of published randomised trials. A study of the GISCAD(Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 2000;11:837-43.
151) Macdonald JS, Smalley SR, Benedetti J, et al:Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
152) Nashimoto A, Nakajima T, Furukawa H, et al:Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer:Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003;21:2282-7.
153) Cunningham D, Allum WH, Stenning SP, et al:Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
154) Nakajima T, Kinoshita T, Nashimoto A, et al:Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg 2007;94:1468-76.
155) Sakuramoto S, Sasako M, Yamaguchi T, et al:Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-20.
156) ”GASTRIC(Global Advanced/Adjuvant Stomach Tumor Research International Collaboration)Group”:Benefit of adjuvant chemotherapy for resectable gastric cancer:a meta-analysis. JAMA 2010;303:1729-37.
157) Di Costanzo F, Gasperoni S, Manzione L, et al:Adjuvant chemotherapy in completely resected gastric cancer:a randomized phase Ⅲ trial conducted by GOIRC. J Natl Cancer Inst 2008;100:388-98.
158) Schwartz GK, Winter K, Minsky BD, et al:Randomized phase Ⅱ trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer(RTOG-0114). J Clin Oncol 2009;27:1956-62.
159) Kodera Y, Ishiyama A, Yoshikawa T, et al:A feasibility study of postoperative chemotherapy with S-1 and cisplatin(CDDP)for gastric carcinoma(CCOG0703). Gastric Cancer 2010;13:197-203.
160) Sasako M, Sakuramoto S, Katai H, et al:Five-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage Ⅱ or Ⅲ gastric cancer. J Clin Oncol 2011;29:4387-93.
161) Messager M, Lefevre JH, Pichot-Delahaye V, et al:The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma:a multicenter comparative study. Ann Surg 2011;254:684-93.
162) Takahari D, Hamaguchi T, Yoshimura K, et al:Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer. Cancer Chemother Pharmacol 2011;67:1423-8.
163) Becker K, Reim D, Novotny A, et al:Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery. Ann Surg 2012;256:1002-7.
164) Lee J, Lim do H, Kim S, et al:Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection:the ARTIST trial. J Clin Oncol 2012;30:268-73.
165) Bang YJ, Kim YW, Yang HK, et al:Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC):a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-21.
166) Smalley SR, Benedetti JK, Haller DG, et al:Updated analysis of SWOG-directed intergroup study 0116:a phase Ⅲ trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327-33.
167) Shen L, Shan YS, Hu HM, et al:Management of gastric cancer in Asia:resource-stratified guidelines. Lancet Oncol 2013;12:e535-47.
168) Piessen G, Messager M, Le Malicot K, et al:Phase Ⅱ/Ⅲ multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas -PRODIGE 19 -FFCD1103 -ADCI002. BMC Cancer 2013;13:281.
169) Kang YK, Chang HM, Yook JH, et al:Adjuvant chemotherapy for gastric cancer:a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy(AMC0201). Br J Cancer 2013;108:1245-51.